:: 08, Aug 2014 :: A*STAR SCIENTISTS MAKE BREAKTHROUGHS IN OVARIAN CANCER RESEARCH

[5] 9083 genes and their mutational patterns were examined from the retrospective data of 334 HG-SOC tumor samples provided by The Cancer Genome Atlas Research Network for study by the research and clinical community

________________________________________________________________

Image attached: Figure 1. Mouse ovary isencapsulated by asingle layer ofcellscalled ovary surface epithelium (indicated by black arrows). These cellsare long believed tobe thecancer cell of origin of ovarian cancer in humans.

Annex B findings at A*STARs bioinformatics institute hold potential for personalised treatment of major type ovarian cancer

Scientists at A*STARs Bioinformatics Institute have identified genes whose mutation status could be used for prognosis and development of personalized treatment for high-grade serous ovarian carcinoma (HG-SOC), a major type of ovarian cancer.

Besides identification of CHEK2 as a biomarker for poor prognosis, the team of scientists also identified a prognostic signature comprising 21 genes that could be used to stratify patients diagnosed with HG-SOC into subgroups with high- or low- risk of mortality within five years of diagnosis. Patients identified as high-risk had a five-year survival rate of 6%, and appeared to be twice as likely to exhibit resistance to therapy in contrast to those in the low-risk group. Besides determining the effectiveness of treatments, this prognostic signature would allow patients with poor prognosis to be identified even in the absence of mutations in CHEK2 by determining the mutational status of the other 20 genes in the profile.

Read this article:
:: 08, Aug 2014 :: A*STAR SCIENTISTS MAKE BREAKTHROUGHS IN OVARIAN CANCER RESEARCH